Cargando…
OR11-3 Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
BACKGROUND: Destructive thyroiditis is the most common endocrine immune related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE. Nevertheless in patients with enlarged thyroid volume and a po...
Autores principales: | Antonangeli, Lucia, Antonuzzo, Andrea, Brogioni, Sandra, Chella, Antonio, Cremolini, Chiara, Latrofa, Francesco, Lupi, Isabella, Marcocci, Claudio, Montanelli, Lucia, Pierotti, Laura, Santini, Ferruccio, Sardella, Chiara, Sgrò, Daniele, Viola, Nicola, Brancatella, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627186/ http://dx.doi.org/10.1210/jendso/bvac150.1653 |
Ejemplares similares
-
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade
por: Brancatella, Alessandro, et al.
Publicado: (2022) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021) -
RF35 | PSAT257 The Severity of Subacute Thyroiditis Depends on Its Causative Agent
por: Brancatella, Alessandro, et al.
Publicado: (2022) -
PSAT382 Characterization of Ultrasound and Cytological Features Identifying Thyroid Nodules with Aggressive Behavior: From Histology to Clinic
por: Latrofa, Francesco, et al.
Publicado: (2022)